{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:11:39Z","timestamp":1792699899120,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.idc.2013.10.002","type":"journal-article","created":{"date-parts":[[2013,12,8]],"date-time":"2013-12-08T03:46:03Z","timestamp":1386474363000},"page":"49-59","source":"Crossref","is-referenced-by-count":88,"title":["Management of Urinary Tract Infections From Multidrug-Resistant Organisms"],"prefix":"10.1016","volume":"28","author":[{"given":"Kalpana","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Bhadelia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.idc.2013.10.002_bib1","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1086\/367653","article-title":"Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection","volume":"36","author":"Engemann","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2013.10.002_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/archinte.162.2.185","article-title":"Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species","volume":"162","author":"Cosgrove","year":"2002","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.idc.2013.10.002_bib3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/archinte.158.5.522","article-title":"Enterococcus faecium bacteremia: does vancomycin resistance make a difference?","volume":"158","author":"Stosor","year":"1998","journal-title":"Arch Intern Med"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2013.10.002_bib4","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/499406","article-title":"The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs","volume":"42","author":"Cosgrove","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2013.10.002_bib5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/cid\/cis942","article-title":"Community-associated extended-spectrum beta-lactamase-producing Escherichia coli infection in the United States","volume":"56","author":"Doi","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2013.10.002_bib6","doi-asserted-by":"crossref","first-page":"e36649","DOI":"10.1371\/journal.pone.0036649","article-title":"Drugs of last resort? The use of polymyxins and tigecycline at US Veterans Affairs medical centers, 2005-2010","volume":"7","author":"Huttner","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.idc.2013.10.002_bib7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jama.281.8.736","article-title":"Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women","volume":"281","author":"Gupta","year":"1999","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.idc.2013.10.002_bib8","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1128\/AAC.01377-06","article-title":"Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates","volume":"51","author":"Pitout","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.idc.2013.10.002_bib9","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1086\/421094","article-title":"Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes","volume":"38","author":"Pitout","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2013.10.002_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2013.10.002_bib11","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/jac\/dkl035","article-title":"Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases","volume":"57","author":"Calbo","year":"2006","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2013.10.002_bib12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/jac\/dkm144","article-title":"Community emergence of CTX-M type extended-spectrum beta-lactamases among urinary Escherichia coli from women","volume":"60","author":"Ho","year":"2007","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.idc.2013.10.002_bib13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.diagmicrobio.2007.06.012","article-title":"Antimicrobial resistance in Escherichia coli outpatient urinary isolates from women: emerging multidrug resistance phenotypes","volume":"59","author":"Ho","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2013.10.002_bib14","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1128\/AAC.00576-07","article-title":"First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system","volume":"51","author":"Lewis","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2013.10.002_bib15","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/JCM.42.3.1089-1094.2004","article-title":"Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients","volume":"42","author":"Rodriguez-Bano","year":"2004","journal-title":"J\u00a0Clin Microbiol"},{"issue":"11","key":"10.1016\/j.idc.2013.10.002_bib16","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/508877","article-title":"Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge","volume":"43","author":"Rodriguez-Bano","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2013.10.002_bib17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/jac\/dkh424","article-title":"Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK","volume":"54","author":"Woodford","year":"2004","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.idc.2013.10.002_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10096-007-0401-6","article-title":"Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli","volume":"27","author":"Kang","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2013.10.002_bib19","first-page":"165","article-title":"Vital signs: carbapenem-resistant Enterobacteriaceae","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"10.1016\/j.idc.2013.10.002_bib20","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1086\/591861","article-title":"NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007","volume":"29","author":"Hidron","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"10.1016\/j.idc.2013.10.002_bib21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.mcna.2013.03.006","article-title":"Management of urinary tract infections in the era of increasing antimicrobial resistance","volume":"97","author":"Shepherd","year":"2013","journal-title":"Med Clin North Am"},{"issue":"3","key":"10.1016\/j.idc.2013.10.002_bib22","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dkg352","article-title":"Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS)","volume":"52","author":"Zhanel","year":"2003","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.idc.2013.10.002_bib23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11908-010-0138-8","article-title":"Treatment of resistant enterococcal urinary tract infections","volume":"12","author":"Swaminathan","year":"2010","journal-title":"Curr Infect Dis Rep"},{"issue":"10","key":"10.1016\/j.idc.2013.10.002_bib24","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1128\/JCM.01501-13","article-title":"Long term carriage of vancomycin-resistant enterococci in patients discharged from hospital: a 12-year retrospective cohort study","volume":"51","author":"Karki","year":"2013","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.idc.2013.10.002_bib25","series-title":"Mandell, Douglas, and Bennett's principles and practice of infectious diseases","author":"Mandell","year":"2010"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2013.10.002_bib26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1469-0691.2007.01852.x","article-title":"Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline","volume":"14","author":"Garau","year":"2008","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.idc.2013.10.002_bib27","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1128\/JCM.02071-06","article-title":"Molecular epidemiology of Staphylococcus saprophyticus isolated from women with uncomplicated community-acquired urinary tract infection","volume":"45","author":"Widerstrom","year":"2007","journal-title":"J\u00a0Clin Microbiol"},{"issue":"14","key":"10.1016\/j.idc.2013.10.002_bib28","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMoa025025","article-title":"Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene","volume":"348","author":"Chang","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.idc.2013.10.002_bib29","doi-asserted-by":"crossref","first-page":"E84","DOI":"10.1111\/j.1469-0691.2012.03773.x","article-title":"Predictive value of Escherichia coli susceptibility in strains causing asymptomatic bacteriuria for women with recurrent symptomatic urinary tract infections receiving prophylaxis","volume":"18","author":"Beerepoot","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.idc.2013.10.002_bib30","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/cid\/cis947","article-title":"Editorial commentary: extended-spectrum beta-lactamase-producing Escherichia coli in the United States: time to rethink empirical treatment for suspected E. coli infections?","volume":"56","author":"Foxman","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.idc.2013.10.002_bib31","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1128\/AAC.01760-09","article-title":"Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli","volume":"54","author":"Auer","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.idc.2013.10.002_bib32","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/jac\/dkq237","article-title":"Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials","volume":"65","author":"Falagas","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.idc.2013.10.002_bib33","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/jac\/dkq346","article-title":"Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli","volume":"65","author":"Oteo","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.idc.2013.10.002_bib34","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2013.10.002_bib35","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1128\/AAC.01519-08","article-title":"Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases","volume":"53","author":"Prakash","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 4","key":"10.1016\/j.idc.2013.10.002_bib36","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1086\/500663","article-title":"Extended-spectrum beta-lactamases and clinical outcomes: current data","volume":"42","author":"Ramphal","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.idc.2013.10.002_bib37","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.2165\/00003495-200565150-00013","article-title":"Ertapenem: a review of its use in the treatment of bacterial infections","volume":"65","author":"Keating","year":"2005","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.idc.2013.10.002_bib38","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1128\/JCM.02494-07","article-title":"Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective","volume":"46","author":"Curcio","year":"2008","journal-title":"J\u00a0Clin Microbiol"},{"issue":"9","key":"10.1016\/j.idc.2013.10.002_bib39","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1177\/0091270011416938","article-title":"Tigecycline pharmacokinetics in subjects with various degrees of renal function","volume":"52","author":"Korth-Bradley","year":"2012","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.idc.2013.10.002_bib40","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1128\/JCM.01340-07","article-title":"Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli","volume":"46","author":"Krueger","year":"2008","journal-title":"J\u00a0Clin Microbiol"},{"issue":"12","key":"10.1016\/j.idc.2013.10.002_bib41","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1128\/AAC.00387-11","article-title":"Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine","volume":"55","author":"Satlin","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.idc.2013.10.002_bib42","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/cid\/cit334","article-title":"Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens","volume":"57","author":"Sandri","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2013.10.002_bib43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1476-0711-11-32","article-title":"Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports","volume":"11","author":"Lee","year":"2012","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"8","key":"10.1016\/j.idc.2013.10.002_bib44","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1469-0691.2011.03553.x","article-title":"Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?","volume":"17","author":"Daikos","year":"2011","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.idc.2013.10.002_bib45","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/520427","article-title":"Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA)","volume":"29","author":"Warren","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2013.10.002_bib46","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/00003495-199753040-00007","article-title":"Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections","volume":"53","author":"Patel","year":"1997","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2013.10.002_bib47","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.ijantimicag.2003.09.002","article-title":"Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections","volume":"23","author":"Naber","year":"2004","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.idc.2013.10.002_bib48","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003495-200262030-00002","article-title":"Treatment options for vancomycin-resistant enterococcal infections","volume":"62","author":"Linden","year":"2002","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.idc.2013.10.002_bib49","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1086\/523276","article-title":"Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus","volume":"28","author":"Pogue","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"9","key":"10.1016\/j.idc.2013.10.002_bib50","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1517\/13543784.13.9.1159","article-title":"Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections","volume":"13","author":"Eisenstein","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"10.1016\/j.idc.2013.10.002_bib51","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/jac\/dkt118","article-title":"Activity of biapenem (RPX2003) combined with the boronate beta-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae","volume":"68","author":"Livermore","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.idc.2013.10.002_bib52","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1128\/AAC.00641-09","article-title":"In\u00a0vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases","volume":"53","author":"Endimiani","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.idc.2013.10.002_bib53","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/AAC.02418-12","article-title":"In\u00a0vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine beta-lactamase inhibitor, against anaerobic bacteria","volume":"57","author":"Goldstein","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2013.10.002_bib54","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/AAC.05927-11","article-title":"In\u00a0vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria","volume":"56","author":"Hirsch","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2013.10.002_bib55","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/jac\/dkt050","article-title":"Activity of BAL30072 alone or combined with beta-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters","volume":"68","author":"Mushtaq","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.idc.2013.10.002_bib56","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1128\/AAC.01397-09","article-title":"In\u00a0vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates","volume":"54","author":"Ishii","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2013.10.002_bib57","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/beta-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.idc.2013.10.002_bib58","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/cid\/cit152","article-title":"10 x '20 Progress\u2013development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America","volume":"56","author":"Boucher","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2013.10.002_bib59","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/cir793","article-title":"Can we really use ss-lactam\/ss-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ss-lactamase-producing\u00a0bacteria?","volume":"54","author":"Perez","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2013.10.002_bib60","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.bcp.2011.07.077","article-title":"New antimicrobial agents on the horizon","volume":"82","author":"Bush","year":"2011","journal-title":"Biochem Pharmacol"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552013000809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552013000809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T09:26:41Z","timestamp":1538990801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552013000809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0891552013000809"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2013.10.002","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}